Ann Arbor, MI: Over 40 percent of patients with multiple sclerosis say that they have consumed either cannabis or cannabinoid products in the past year, according to survey data published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical. That percentage is nearly twice that of the national average.
Investigators with the University of Michigan collected data from a national sampling of over 1,000 patients with MS. Forty-two percent of respondents affirmed that they had used either cannabis or cannabinoid products within the past year – with 90 percent of those respondents describing their use as medical. Those utilizing cannabinoids reported that they were most effective for improving sleep and reducing tremor frequency as well as for mitigating nausea and anxiety.
Full text of the study, “Cannabisnoid use among Americans with MS: Current trends and gaps in knowledge,” appears in Multiple Sclerosis Journal – Experimental, Translational and Clinical. Additional information on cannabis and MS is available from NORML.